Value
8.3/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 10.0 |
| P/S | 8.6 |
| EV/EBITDA | 8.8 |
| Fwd P/E | 9.5 |
| Analyst target | 6.0 |
- ▸Forward P/E: 8.4x
- ▸Attractively valued
RIGL · Why this verdict
Why Rigel Pharmaceuticals (RIGL) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.1/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Rigel shows wide-moat characteristics and has compounded strong returns with growth, evidenced by an excellent 174% ROE and a strong Piotroski F-Score of 7 out of 9 — indicating genuinely strong underlying fundamentals rather than a speculative biotech story. Quality breakdown | The Piotroski F-Score should hold at 6 or above and ROE should remain elevated, above 100%, over the next several quarters. | →Stable |
| CounterA 22% FCF/NI conversion is flagged as an earnings-quality red flag, meaning the strong-fundamentals narrative may be built on accounting earnings that don't fully convert to cash. | ||
The V8 system flags a cyclical trap: forward P/E of 8x looks cheap only relative to a trailing P/E that reflects a likely cyclical peak in earnings, with consensus expecting a roughly 75% earnings decline ahead. Warnings | Forward earnings estimates should not fall further from current levels once the anticipated cyclical decline plays out, stabilizing the forward P/E. | →Stable |
| CounterIf the earnings decline is driven by one-off items rather than the core business, the cyclical-trap framing may overstate the risk to normalized earnings power. | ||
The V9 asymmetry gate narrowly failed (1.4 versus the 1.5 threshold), even as the engine sizes this as a small initial position despite flagging high conviction from strong data quality and signal alignment, indicating the risk/reward is close to attractive but not quite there at the current spot price. Engine gate (failed) | The asymmetry ratio should cross above 1.5 within the next couple of months, either via a modest pullback or a price-target increase. | →Stable |
| CounterA gate failure by only 0.1 points is close enough to noise that it may not represent a meaningful signal against adding to the position. | ||
RSI is overbought at 79 with a flattening-to-negative 200-day moving average slope, which the engine flags as late-cycle distribution risk even though the death-cross momentum gate was exempted due to quality. Momentum breakdown | RSI should cool from 79 toward more sustainable levels without a disorderly price decline. | →Stable |
| CounterThe death-cross exemption for high-quality names suggests the engine itself believes this technical pattern is less predictive here than for a typical stock, given Rigel's quality score. | ||
The engine identifies a short-squeeze setup — 19% short interest against a quality score of 7.5 — suggesting bears may be pressed to cover if the company's next earnings report beats expectations. Risk breakdown | Short interest should decline from 19% as the quality thesis plays out, either through covering or reduced new shorting. | →Stable |
| CounterHigh short interest against a wide-moat, high-quality name could also reflect sophisticated investors correctly betting on the cyclical earnings decline overwhelming the quality narrative. | ||
Rigel shows wide-moat characteristics and has compounded strong returns with growth, evidenced by an excellent 174% ROE and a strong Piotroski F-Score of 7 out of 9 — indicating genuinely strong underlying fundamentals rather than a speculative biotech story.
→StableQuality breakdown
- Expectation
- The Piotroski F-Score should hold at 6 or above and ROE should remain elevated, above 100%, over the next several quarters.
CounterA 22% FCF/NI conversion is flagged as an earnings-quality red flag, meaning the strong-fundamentals narrative may be built on accounting earnings that don't fully convert to cash.
The V8 system flags a cyclical trap: forward P/E of 8x looks cheap only relative to a trailing P/E that reflects a likely cyclical peak in earnings, with consensus expecting a roughly 75% earnings decline ahead.
→StableWarnings
- Expectation
- Forward earnings estimates should not fall further from current levels once the anticipated cyclical decline plays out, stabilizing the forward P/E.
CounterIf the earnings decline is driven by one-off items rather than the core business, the cyclical-trap framing may overstate the risk to normalized earnings power.
The V9 asymmetry gate narrowly failed (1.4 versus the 1.5 threshold), even as the engine sizes this as a small initial position despite flagging high conviction from strong data quality and signal alignment, indicating the risk/reward is close to attractive but not quite there at the current spot price.
→StableEngine gate (failed)
- Expectation
- The asymmetry ratio should cross above 1.5 within the next couple of months, either via a modest pullback or a price-target increase.
CounterA gate failure by only 0.1 points is close enough to noise that it may not represent a meaningful signal against adding to the position.
RSI is overbought at 79 with a flattening-to-negative 200-day moving average slope, which the engine flags as late-cycle distribution risk even though the death-cross momentum gate was exempted due to quality.
→StableMomentum breakdown
- Expectation
- RSI should cool from 79 toward more sustainable levels without a disorderly price decline.
CounterThe death-cross exemption for high-quality names suggests the engine itself believes this technical pattern is less predictive here than for a typical stock, given Rigel's quality score.
The engine identifies a short-squeeze setup — 19% short interest against a quality score of 7.5 — suggesting bears may be pressed to cover if the company's next earnings report beats expectations.
→StableRisk breakdown
- Expectation
- Short interest should decline from 19% as the quality thesis plays out, either through covering or reduced new shorting.
CounterHigh short interest against a wide-moat, high-quality name could also reflect sophisticated investors correctly betting on the cyclical earnings decline overwhelming the quality narrative.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Rigel Pharmaceuticals is flagged by the engine as a wide-moat, high-quality business trading cheaply, but consensus expects a sharp cyclical earnings decline ahead, and the asymmetry gate has narrowly failed even as short interest sets up a potential squeeze.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 8.1 |
| Current ratio | 8.8 |
| FCF quality | 1.7 |
| Moat | 9.0 |
| Rule of 40 | 5.5 |
| Piotroski F | 7.8 |
- ▸Excellent ROE: 174%
- ▸Earnings quality RED FLAG: 22% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
2.5/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.1 |
| EPS growth | 0.0 |
Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 0.0 |
- ▸Overbought (RSI 89)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 89 (late-cycle distribution risk)
Sentiment
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.5 |
| Price target | 8.4 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 27%
Insider
5.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 10.0 |
- ▸Modest insider selling — $160,425 (0.022% of mkt cap)
- ▸Institutions accumulating
Peer rank
7.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 9.5 |
| quality rank | 10.0 |
| growth rank | 4.6 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.6 |
| support resistance | 0.4 |
| 52w position | 6.3 |
| gap | 7.0 |
Risk (lower is worse)
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.3 |
| days to cover | 0.0 |
| volatility | 1.6 |
| put call | 9.9 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 6.5 |
| debt equity | 9.5 |
- ▸Short squeeze setup: 19% short, quality 7.5
- ▸High IV: 82%
- ▸Above max pain $20
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Wide-moat business. Accumulate on weakness. | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_E_WIDE_MOAT|L3:NEWS_MOD=-1Passed (7)
- MOMENTUM:6.2>=5.5
- INSIDER:OK
- DEATH_CROSS:QUALITY_MOMENTUM_EXEMPT
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:28d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.7<1.5@spot
Warning (2)
- DEATH_CROSS:quality=7.9>=7.5+momentum=6.2>=5.0 exempted
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.71
Upside
+10.7%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 89
EdgeInst Constrain — Small cap ($0.7B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The HOLD_IF_HOLDING verdict reflects the ASYMMETRY gate's 0.7<1.5@spot outcome against Value at 8.3 and asymmetric R:R of 0.71.
The strongest dimensions are Value at 8.3, Quality at 7.9, and Peer rank at 7.2; the weakest are Growth at 2.5, Technical at 3.6, and Risk (lower is worse) at 4.9. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.71 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Strong Fundamentals
Trip ifFCF/NI conversion falls below 10% for 2 consecutive quarters.
- P2Cyclical Earnings Trap Risk
Trip ifConsensus forward EPS estimates are cut by more than 30% from current levels within 2 quarters.
- P3Marginal Asymmetry Gate Failure
Trip ifAsymmetry ratio falls below 1.0 from the current 1.45.
- P4Late Cycle Technical Risk
Trip ifRSI falls below 30 within 2 months, marking a sharp reversal from the current 79.
- P5Short Squeeze Setup
Trip ifShort interest rises above 25% of float from the current 19%.